- Home
- FINV vs DNLI Comparison
FINV vs DNLI Comparison
Compare FINV & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINV
- DNLI
- Stock Information
- Founded
- FINV 2007
- DNLI 2013
- Country
- FINV China
- DNLI United States
- Employees
- FINV N/A
- DNLI N/A
- Industry
- FINV Finance: Consumer Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FINV Finance
- DNLI Health Care
- Exchange
- FINV Nasdaq
- DNLI Nasdaq
- Market Cap
- FINV 2.0B
- DNLI 1.9B
- IPO Year
- FINV N/A
- DNLI 2017
- Fundamental
- Price
- FINV $8.30
- DNLI $14.37
- Analyst Decision
- FINV Buy
- DNLI Strong Buy
- Analyst Count
- FINV 2
- DNLI 15
- Target Price
- FINV $11.40
- DNLI $33.92
- AVG Volume (30 Days)
- FINV 1.3M
- DNLI 1.4M
- Earning Date
- FINV 05-19-2025
- DNLI 05-06-2025
- Dividend Yield
- FINV 3.09%
- DNLI N/A
- EPS Growth
- FINV 8.38
- DNLI N/A
- EPS
- FINV 1.24
- DNLI N/A
- Revenue
- FINV $1,792,713,209.00
- DNLI N/A
- Revenue This Year
- FINV $14.79
- DNLI N/A
- Revenue Next Year
- FINV $10.77
- DNLI $384.25
- P/E Ratio
- FINV $6.70
- DNLI N/A
- Revenue Growth
- FINV 3.85
- DNLI N/A
- 52 Week Low
- FINV $4.63
- DNLI $10.57
- 52 Week High
- FINV $11.08
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- FINV 51.55
- DNLI 46.97
- Support Level
- FINV $8.17
- DNLI $13.36
- Resistance Level
- FINV $8.72
- DNLI $16.97
- Average True Range (ATR)
- FINV 0.29
- DNLI 0.95
- MACD
- FINV 0.11
- DNLI -0.06
- Stochastic Oscillator
- FINV 73.75
- DNLI 28.08
About FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.